Changes and significance of serum NGAL ,COX-2 and PG in patients with gastric cancer / 国际检验医学杂志

ABSTRACT

Objective To study the changes and significance of serum neutrophil gelatinase associated li-pocalin (NGAL ) ,cyclooxygenase 2 (COX-2 ) and pepsinogen (PG ) in the patients with gastric cancer . Methods Sixty cases of gastric cancer in this hospital from April 2015 to April 2017 were selected as the ob-servation group ,and contemporaneous 60 healthy subjects were selected as the control group .The double-anti-body sandwich enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of serum NGAL , COX-2 ,PGⅠ ,PG Ⅱ and PG Ⅰ /PGⅡ (PGR) in the two group .The results were compared .The relationship between serum NGAL and COX-2 with the clinicopathological parameters of gastric cancer was analyzed . Results The levels of serum NGAL and COX-2 in the observation group were (23 .43 ± 8 .34)ng/mL and (41 .44 ± 9 .51)ng/mL respectively ,which were higher than (11 .73 ± 2 .81)ng/mL and (16 .89 ± 6 .26)ng/mL in the control group ,the difference was statistically significant (P<0 .05) .Serum PGⅠ and PGR levels in the observation group were(13 .07 ± 20 .19)ng/mL and (2 .69 ± 1 .41) ,which were lower than (60 .15 ± 18 .70) ng/mL and (5 .08 ± 1 .86) in the control group ,the difference was statistically significant (P<0 .05) .The ser-um NGAL level in the patients with TNM stage Ⅰ + Ⅱwas significantly lower than that in the patients with TNM stage Ⅲ + Ⅳ ,the difference was statistically significant (P<0 .05);the serum NGAL level in the pa-tients with distant metastasis was significantly higher than that in the patients without distant metastasis ,the difference was statistically significant (P<0 .05) .The serum COX-2 level in the patients with TNM stage Ⅰ +Ⅱwas significantly lower than that in the patients with TNM stage Ⅲ + Ⅳ ,the difference was statistically sig-nificant(P<0 .05) .Conclusion Serum NGAL ,COX-2 and PG can serve as the effective indicators for gastric cancer screening ,disease condition judgment and prognosis assessment in gastric cancer .